Visit us at COMPAMED in Hall 8a at Booth 8aJ07 Sarstedt, September 1, 2025 At this year's COMPAMED in Düsseldorf , MeKo® will once again showcase its latest developments in high-precision laser processing and medical device innovation. As one of the leading international trade fairs for the medical technology supply sector, COMPAMED is the ideal platform for MeKo to share its expertise and connect with medical device manufacturers from around the world. This year marks a special milestone : MeKo® celebrates 30 years since its first stent project in 1995 . Since then, the company has developed into a trusted partner for OEMs and start-ups worldwide. With more than three decades of experience, MeKo® continues to lead the way in precision manufacturing and innovation. MeKo® has further expanded its foundry for magnesium-based materials like Resoloy® . The facility enables precise adjustments to alloy composition and microstructure, supporting tailored development of bioresorbable implants and scaffolds. The in-house foundry enhances flexibility and innovation speed for research and customer projects. One highlight at COMPAMED will be MeKo’s advanced polymer coatings for implants such as stents and heart valve frames. These coatings offer long-term drug elution, enhanced durability and biocompatibility and can be applied to both metallic and bioresorbable materials. Of particular interest is the compatibility with MeKo’s proprietary magnesium alloy Resoloy®. With the newly established MeKo® MedLab , a spin-off from MeKo®, the company now offers in-house testing and validation for materials, components and assembled products. From burst pressure tests to tensile strength and corrosion analysis, MeKo® MedLab ensures that every product meets the highest quality standards and is ready for market approval. We invite all COMPAMED visitors to meet our experts at Booth 8aJ07 in Hall 8a . Experience our latest innovations and explore how MeKo® can support your next-generation medical devices from concept to certification.

Fort Wayne Metals, Vascotube, EUROFLEX, ADMEDES, and MeKo MedTech form collective to address growing market for pure, consistent, high-performance Nitinol GLOBAL RELEASE — June 25, 2025 — Five leading companies in the medical device industry have launched the PRIME project – a strategic initiative dedicated to advancing the consistency, scalability, and performance of Nitinol materials. PRIME stands for PRoficient Ingot Material Evaluation and brings together deep technical expertise from every stage of the Nitinol value chain. Founding PRIME members include Fort Wayne Metals, Vascotube, EUROFLEX, ADMEDES, and MeKo MedTech . Project Goals and Industry Impact PRIME was created to advance Nitinol materials while strengthening supply chain stability and meeting rising market demands. Through joint testing, real-world validation, and transparent evaluation of new ingot sources, the initiative helps prevent monopolistic dependencies and mitigate future supply risks, essential for the production of critical applications like stents, heart valve frames, and other fatigue-sensitive components. Interest across the industry continues to grow, with plans for expansion underway. “Our ambition with PRIME is to provide the highest-quality Nitinol melt to help build a stronger, more resilient supply chain for the entire industry. This project reflects our long-standing commitment to advancing materials that enable life-saving technologies while ensuring availability and consistency for customers worldwide,” said Jeremy Rohrs , President of Fort Wayne Metals. Project Scope and Technical Publication The PRIME project covers the full process chain — from ingot melting to tube drawing to device manufacturing — and is composed of the following founding members: - Fort Wayne Metals (melting) - EUROFLEX and Vascotube (tube drawing) - ADMEDES and MeKo MedTech (component manufacturing) Their combined efforts will lead to the production and release of a series of joint technical papers, providing the industry with data from the project with the intent of informing and benefiting the market. The papers will be published and available for download on the official PRIME website upon completion. “Our industry depends on reliable Nitinol for life-saving devices. PRIME was formed to future-proof the supply chain by combining expertise across all production stages,” said Jakob Dohse , CEO of MeKo MedTech. “Using advanced melting, drawing, and manufacturing techniques ensures purity and consistent composition throughout the process and we’re excited about the value and quality this group will be contributing to the Nitinol market.” Further publications and application-specific results are planned to promote industry-wide transparency and knowledge sharing. Currently, ingots, tubes, and components made from Fort Wayne Metals’ melted Nitinol are available for purchase, empowering companies to conduct their own testing and production measures. To stay informed, visit www.prime-ingot.com or join the PRIME project LinkedIn group .

Strengthening Global MedTech with a New Trade-Free Zone Facility Sarstedt, May 14, 2025 With over 30 years of experience in high-precision laser material processing, the German company MeKo announces the opening of its new subsidiary, MeKo MedTech S.A. , in Costa Rica. This expansion marks the company’s first site outside of Germany and highlights its commitment to innovation, sustainable growth, and proximity to key strategic markets in the Americas. Kai Leymann , President of MeKo MedTech S.A., expert in nitinol and medical device manufacturing, will lead the new operation. Regarding the expansion, he commented: “MeKo has a strong culture of innovation and development. I’m excited to bring that spirit to a new facility in a country known for its warm and welcoming culture. We already feel how Costa Rica’s energy and enthusiasm enrich our company’s strengths with a healthy dose of ‘Pura Vida’ spirit.” For Manuel Tovar , Minister of Foreign Trade, MeKo’s decision reinforces Costa Rica’s position as a global leader in the medical technology industry. As the Minister stated, “The medical device sector, declared of public and national interest, accounts for more than 40% of the country’s exports and generates quality employment for over 58,000 people. MeKo’s expansion validates the strength of Costa Rica’s ecosystem, which combines highly skilled talent with an institutional framework that fosters innovation, sustainability, and investment in healthcare”. With a 1,400-square-meter facility, the company will contribute to local economic growth by creating high-quality jobs and fostering the transfer of specialized technical knowledge. MeKo aligns with Costa Rica’s dedication to renewable energy , leveraging the country’s, on average, 97% clean energy supply to support environmentally responsible manufacturing. For Laura López , CEO of Costa Rica’s Trade & Investment Promotion Agency (PROCOMER), this investment reaffirms the country’s positioning as a strategic partner for companies in the sector: “PROCOMER is proud to support investments such as MeKo’s, which generate knowledge transfer, quality jobs, and demonstrate a business commitment to sustainability and excellence. The arrival of MeKo in Costa Rica, whose capital is from Germany, represents an important step forward in our strategy to diversify the origin of investments. Furthermore, it consolidates Costa Rica’s position as a regional leader in medical device manufacturing, thanks to the strength of our productive ecosystem, the quality of our human talent, and the competitive conditions we offer investors.” For MeKo’s clients across America, the new facility brings significant advantages. Being located in the Metro Free Zone & Business Park allows the company to optimize logistics, reduce lead times, and benefit from Costa Rica’s favorable trade agreements. The free-trade zone framework provides duty-free access for production, enabling a more efficient and streamlined operation while maintaining the high-quality standards that define the company.

MeKo Leverages Simulation to Optimize Medical Devices Sarstedt, 27. August 2024 MeKo is a global contract manufacturer of precision components like stents and heart valve frames, for the largest OEMs and small start-ups. In addition to precision manufacturing with exceptionally tight tolerances, MeKo employs state-of-the-art simulation techniques to revolutionize the development of medical devices. One of our most powerful tools is Finite Element Analysis (FEA), which enables the virtual simulation and optimization of complex structures and their behavior under various conditions. Engaging MeKo experts offers numerous benefits, including faster design iterations, reducing costs while minimizing risks for patients. By identifying and correcting potential design concerns early on, product safety and reliability are improved before starting costly clinical trials. Another advantage at MeKo is the close collaboration with customers. This allows for the development of tailored solutions that meet the specific requirements of each project. With over 30 years of experience, MeKo delivers fast and precise simulation results that form the basis for innovative and reliable medical components.

New bioresorbable materials at COMPAMED / MEDICA Sarstedt, September 16, 2022 MeKo is known as a contract manufacturer of medical components with particularly tight tolerances, such as stents or heart valve frames. At this year’s COMPAMED / MEDICA trade fair, MeKo will present PolyMediX®, its innovative polymer tubing used for the manufacturing of high-precision bioresorbable implants. The high-precision PolyMediX® tubes are made using an innovative manufacturing process developed by MeKo. Thanks to the particularly gentle manufacturing process, PolyMediX® enables direct and non-destructive integration of medications into the tube walls. In this case, poly has a double meaning. It stands for “polymer”, but it also refers to the multiple possibilities offered by this manufacturing process. In addition to the ability to use a wide range of different polymers or different combinations of polymers and active agents for medi cal implants, this manufacturing process also makes it possible to integrate multiple active agents X or set an active agent gradient between the outside and the inside of the tube wall. With PolyMediX®, MeKo makes it possible to manufacture implants that are perfectly adapted to individual customer requirements from polymer materials. In 2011, MeKo presented Resoloy® , the resorbable magnesium alloy for scaffolds, which is already being used for resorbable implants today. With the PolyMediX® platform, MeKo is expanding its repertoire in the field of bioresorbable materials and utilizing its unique expertise in the production of bioresorbable implants.

The world’s first device to stop small abdominal aortic aneurysms progression Sarstedt, October 27, 2023 Around five percent of the Western population suffers from an abdominal aortic aneurysm. An abdominal aortic aneurysm is defined as bulging of the main artery of the body (aorta) in the abdominal cavity. The larger the aneurysm becomes the higher the risk for rupture gets. In most cases, patients who suffer from an aneurysm rupture do not survive (up to 80 %). Despite the high incidence of the disease, there is currently no therapy available that prevents small bulges from developing or existing bulges from becoming larger – and thus increasing the risk of rupture. Approximately 90 % of abdominal aneurysms are diagnosed at an early stage when they are small and could thus be treated early on. To close this gap and help as many patients as possible, the German start-up Angiolutions has developed an innovative device. The implant is placed during a minor, minimally invasive procedure, protecting the aneurysm from harmful biomechanical stress. Angiolutions relies on the contract manufacturer MeKo MedTech with close collaboration To produce the implant, Angiolutions – an award-winning medical device company – looked for a laser manufacturing specialist with extensive experience manufacturing medical implants and found what they were looking for in MeKo. The components are laser cut with highest precision before undergoing further treatment. Extensive quality tests are carried out at the end of the manufacturing process. "With MeKo, we've found an optimal partner to bring our vision to life. Their comprehensive support, spanning from production to lab testing, has been instrumental in helping us deliver a device that truly meets our medical objectives. The professionalism of MeKo's services has been consistently outstanding," extols Dr. Uwe Raaz, Co-CEO of Angiolutions. Co-CEO Dr. Isabel Schellinger echoes this sentiment after touring the production facility: "We were genuinely impressed by MeKo's state-of-the art equipment, their precision measurement systems, and specialized amenities such as the clean rooms." Markus Binder, who oversees the Angiolutions account, is also enthusiastic about the ongoing collaboration, stating, "Partnering with innovative companies such as Angiolutions serves as a substantial motivation for us."